• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence.

作者信息

Saukkonen Jussi J, Powell Krista, Jereb John A

出版信息

Am J Respir Crit Care Med. 2012 Mar 15;185(6):598-9. doi: 10.1164/rccm.201112-2174ED.

DOI:10.1164/rccm.201112-2174ED
PMID:22422902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11291837/
Abstract
摘要

相似文献

1
Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence.监测结核病药物肝毒性：从观点走向证据
Am J Respir Crit Care Med. 2012 Mar 15;185(6):598-9. doi: 10.1164/rccm.201112-2174ED.
2
Adaptation and antituberculosis drug-induced liver injury.
Am J Respir Crit Care Med. 2012 Aug 15;186(4):387-8; author reply 388-9. doi: 10.1164/ajrccm.186.4.387.
3
A comparison between two strategies for monitoring hepatic function during antituberculous therapy.两种抗结核治疗期间肝功能监测策略的比较。
Am J Respir Crit Care Med. 2012 Mar 15;185(6):653-9. doi: 10.1164/rccm.201105-0850OC. Epub 2011 Dec 28.
4
[Tuberculosis treatment in adults].[成人结核病治疗]
Rev Prat. 2012 Apr;62(4):495-501.
5
Antituberculous therapy and acute liver failure.
Lancet. 1995 May 6;345(8958):1171.
6
Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion.监测接受潜伏性结核感染治疗个体的毒性：系统评价与专家意见对比
Eur Respir J. 2015 Apr;45(4):1170-3. doi: 10.1183/09031936.00216814. Epub 2015 Feb 19.
7
Hepatotoxic effects of therapies for tuberculosis.结核病治疗的肝毒性作用。
Nat Rev Gastroenterol Hepatol. 2010 Oct;7(10):543-56. doi: 10.1038/nrgastro.2010.134. Epub 2010 Aug 31.
8
[Paying attention to the prevention and treatment of hepatic injury induced by anti-tuberculosis drugs].关注抗结核药物所致肝损伤的防治
Zhonghua Jie He He Hu Xi Za Zhi. 2019 May 12;42(5):326-329. doi: 10.3760/cma.j.issn.1001-0939.2019.05.003.
9
Management of and risk factors related to hepatotoxicity during tuberculosis treatment.结核病治疗期间肝毒性的管理及相关风险因素
Tuberk Toraks. 2012;60(2):136-44.
10
Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.与利福平-吡嗪酰胺预防性治疗相关的严重肝毒性，该治疗导致一名肝毒性低风险个体需要进行移植。
Clin Infect Dis. 2003 Jun 15;36(12):e158-61. doi: 10.1086/375072. Epub 2003 Jun 6.

引用本文的文献

1
Recent advances in nanogels for drug delivery and biomedical applications.用于药物输送和生物医学应用的纳米凝胶的最新进展。
Biomater Sci. 2024 Nov 19;12(23):6006-6018. doi: 10.1039/d4bm00224e.
2
Diagnosis and management of severe pulmonary and extrapulmonary tuberculosis in critically ill patients: A mini review for clinicians.危重症患者严重肺结核及肺外结核的诊断与管理：给临床医生的小型综述
World J Crit Care Med. 2024 Jun 9;13(2):91435. doi: 10.5492/wjccm.v13.i2.91435.
3
Clinical Features, Biochemical Parameters, and Treatment Adherence of Individuals Who Started the Treatment for Active Pulmonary Tuberculosis during the Pandemic Period.大流行期间开始接受活动性肺结核治疗的患者的临床特征、生化参数及治疗依从性
J Clin Med. 2023 Jul 22;12(14):4843. doi: 10.3390/jcm12144843.
4
The Effectiveness of Silymarin in the Prevention of Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized Controlled Clinical Trial.水飞蓟素预防抗结核药物所致肝毒性的有效性：一项随机对照临床试验
Int J Prev Med. 2023 Apr 26;14:48. doi: 10.4103/ijpvm.ijpvm_81_22. eCollection 2023.
5
Determinants of Response at 2 Months of Treatment in a Cohort of Pakistani Patients with Pulmonary Tuberculosis.一组巴基斯坦肺结核患者治疗2个月时反应的决定因素
Antibiotics (Basel). 2022 Sep 26;11(10):1307. doi: 10.3390/antibiotics11101307.
6
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.利奈唑胺、莫西沙星和吡嗪酰胺治疗肺结核的部分随机试验。
Int J Tuberc Lung Dis. 2021 Apr 1;25(4):305-314. doi: 10.5588/ijtld.20.0513.
7
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
8
Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action.通过创建预测作用模式的分枝杆菌指示菌株来加速早期抗结核药物发现。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00083-18. Print 2018 Jul.
9
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.REMOxTB 研究中与结核病化疗相关的肝毒性。
BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7.
10
Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity.水飞蓟素预防性使用对抗结核药物所致肝毒性的影响。
Tuberc Respir Dis (Seoul). 2017 Jul;80(3):265-269. doi: 10.4046/trd.2017.80.3.265. Epub 2017 Jul 3.

本文引用的文献

1
A comparison between two strategies for monitoring hepatic function during antituberculous therapy.两种抗结核治疗期间肝功能监测策略的比较。
Am J Respir Crit Care Med. 2012 Mar 15;185(6):653-9. doi: 10.1164/rccm.201105-0850OC. Epub 2011 Dec 28.
2
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.中国抗结核药物性肝损伤（ATLI）的发生率、临床特征及其对抗结核治疗的影响。
PLoS One. 2011;6(7):e21836. doi: 10.1371/journal.pone.0021836. Epub 2011 Jul 5.
3
Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.与一线抗结核药物方案相关的药物不良反应。
Int J Tuberc Lung Dis. 2007 Aug;11(8):868-75.
4
An official ATS statement: hepatotoxicity of antituberculosis therapy.美国胸科学会官方声明：抗结核治疗的肝毒性
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. doi: 10.1164/rccm.200510-1666ST.
5
Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.合并或未合并人类免疫缺陷病毒（HIV）感染的结核病患者的不良事件及治疗中断情况
Thorax. 2006 Sep;61(9):791-4. doi: 10.1136/thx.2006.058867. Epub 2006 Jul 14.
6
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.美国胸科学会/疾病控制与预防中心/美国传染病学会：结核病的治疗
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. doi: 10.1164/rccm.167.4.603.
7
Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.活动性结核病患者中一线抗结核药物严重副作用的发生率。
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7. doi: 10.1164/rccm.200206-626OC. Epub 2003 Jan 31.